Analyses of mortality risk in patients with dementia treated with galantamine

Acta Neurologica Scandinavica

Volumn 119, Issue 1, 2009, Pages 22-31

  Feldman, H H ^a   Pirttila, T ^b   Dartigues, J F ^c   Everitt, B ^d   Van Baelen, B ^e   Brashear, H R ^f   Berlin, J A ^f   Battisti, W P ^f   Kavanagh, S ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e SGS Medisearch International NV   (Belgium)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Alzheimer disease; Dementia; Galantamine; Meta analysis; Mortality; Retrieved drop out

Indexed keywords

GALANTAMINE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIINFARCT DEMENTIA; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GALANTAMINE; HUMANS; INSTITUTIONALIZATION; MALE; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; PERSONALITY INVENTORY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 58149083904     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01047.x     Document Type: Article

References (32)

1. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001 56 : 1154 66.
2. Samochocki M, Hoffle A, Fehrenbacher A et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003 305 : 1024 36.
3. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001 16 : 852 7.
4. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000 54 : 2269 76.
5. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000 321 : 1445 9.
6. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001 71 : 589 95.
7. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005 20 : 120 32.
8. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000 54 : 2261 8.
9. Rockwood K, Fay S, Song X, Macknight C, Gorman M. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ 2006 174 : 1099 105.
10. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002 359 : 1283 90.
11. Auchus AP, Brashear HR, Salloway S et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007 69 : 448 58.
12. Winblad B, Gauthier S, Scinto L et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008, March 5 [epub ahead of print].
13. Anonymous. An observational study of the vital status data of patients (living or deceased) who participated in three previous studies of galantamine for the treatment of mild cognitive impairment. NCT00297414. Available at: http://www.clinicaltrials.gov.
14. Feldman H, Wilcock G, Van Baelen B, Kavanagh S. Effect of galantamine on time to residential or nursing home admission. Euro J Neurol 2004 11 : 189.
15. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 44.
16. Roman GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993 43 : 250 60.
17. Anonymous. S.P.C. Reminyl XL 8 mg, 16 mg and 24 mg prolonged release capsules. Available at: http://www.emcmedicines.org.uk.
18. Folstein MF, Folstein SE, Mchugh PR. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 98.
19. Gelinas I, Gauthier L, Mcintyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999 53 : 471 81.
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994 44 : 2308 14.
21. Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004 363 : 2105 15.
22. Anonymous. Efficacy study of MPC-7869 to treat patients with Alzheimer's NCT00105547. Available at: http://www.clinicaltrials.gov/ct/show/NCT00105547 2005 (study start date).
23. Anonymous. European study of 3APS in mild to moderate Alzheimer's disease patients. NCT00217763. Available at: http://www.clinicaltrials.gov/ct/show/ NCT00217763 2005 (study start date).
24. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001 154 : 642 8.
25. Larson EB, Shadlen MF, Wang L et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004 140 : 501 9.
26. Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002 59 : 1764 7.
27. Tschanz JT, Corcoran C, Skoog I et al. Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. Neurology 2004 62 : 1156 62.
28. Dewey ME, Saz P. Dementia, cognitive impairment and mortality in persons aged 65 and over living in the community: a systematic review of the literature. Int J Geriatr Psychiatry 2001 16 : 751 61.
29. Wilcock G, Howe I, Coles H et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003 20 : 777 89.
30. Anonymous. A cardiac safety study of galantamine in the treatment of Alzheimer's disease. NCT00309725. Available at: http://www.clinicaltrials.gov. Results are posted at: http://download.veritasmedicine.com/PDF/CR012118_CSR.pdf.
31. Anonymous. Safety and efficacy of high dose, rapid titration galantamine in patients with Alzheimer's disease. NCT00338117. Available at: http://www.clinicaltrials.gov.
32. Anonymous. An efficacy and safety study of galantamine for the treatment of patients with Alzheimer's disease. NCT00338117. Available at: http://www.clinicaltrials.gov. Results posted at: http://download. veritasmedicine.com/PDF/CR003301_CSR.pdf.